The trajectory of companies tied to the drug's legacy presents a complex investment landscape. While the initial boom generated substantial profits , generic alternatives have significantly impacted sales . Investing in connected pharmaceutical businesses now requires a discerning assessment of patent safeguards, evolving healthcare shifts , and th